{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-015519","form_type":"8-K","ticker":"ATRA","cik":"0001604464","company_name":"Atara Biotherapeutics, Inc.","filed_at":"2022-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.335061+00:00","generated_at":"2026-06-24T02:49:23.990331+00:00","sec_items":["1.01","2.02","2.05","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Atara Q2 net income $18.5M; workforce cut 20%; CCO departure; Bayer deal terminated; FDA supports tab-cel BLA path","bullets":["Net income $18.5M ($0.18/diluted) vs net loss $83.8M in Q2 2021; includes $50.2M gain on ATOM facility sale.","Workforce reduction of ~20% to reduce future annual cash burn by >20%; expects $6M severance charges; cash runway extended to Q1 2024.","Bayer termination agreement: Bayer pays $4.2M, returns rights to ATA2271/ATA3271; license and collab revenue $51.6M in Q2 from termination.","FDA recommended pathway to BLA for tab-cel without new trial; EC approval on track Q4 2022.","Kristin Yarema, SVP & CCO, to depart effective Nov 15, 2022; severance of 12 months base salary."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-015519","json":"https://secwatch.observer/filing/0000950170-22-015519.json","markdown":"https://secwatch.observer/filing/0000950170-22-015519.md","text":"https://secwatch.observer/filing/0000950170-22-015519.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604464/000095017022015519/0000950170-22-015519-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604464/000095017022015519/atra-20220802.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:49:23.990331+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2d6bb29fad","claim":"Kristin Yarema was terminated as Senior Vice President and Chief Commercial Officer at Atara Biotherapeutics, Inc..","evidence_excerpt":"the employment of Kristin Yarema, the Company’s Senior Vice President and Chief Commercial Officer, will terminate effective as of November 15, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1604464/000095017022015519/0000950170-22-015519-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Senior Vice President and Chief Commercial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}